Advertisement

Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia

Published:November 10, 2022DOI:https://doi.org/10.1016/j.jgo.2022.11.002

      Abstract

      Introduction

      Recent data have shown improved outcomes in selected older adults with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (HSCT). Nonetheless, practice patterns for referring and performing HSCT vary. We aimed to evaluate referral, utilization, and reasons for not referring/proceeding to HSCT in older adults with AML.

      Materials and Methods

      This is a single center retrospective analysis of patients aged ≥60 years diagnosed with AML evaluating rates of HSCT referral and utilization. Fisher's exact test was used to compare rates of referral and utilization across age groups and years of diagnosis.

      Results

      Median age of the 97 patients was 70 years (range 61–95); 30% (29/97) were referred for HSCT and of these, 69% (20/29) received HSCT. Common documented reasons (can be multiple) for not referring were performance status (n = 21), advanced age (n = 16), patient refusal (n = 15), refractory disease (n = 14), and prohibitive comorbidity (n = 6). Among patients who were referred but did not receive HSCT (n = 9/29), documented reasons for not proceeding with HSCT were refractory disease (n = 5), advanced age (n = 2), and prohibitive comorbidity (n = 2). HSCT referral and utilization rates significantly decreased with age (p < 0.01) but were generally stable over time from 2014 to 2017 (p = 0.40 for referral and p = 0.56 for utilization).

      Discussion

      Despite improvements in supportive care and HSCT techniques, HSCT referral and utilization rates remained low among older adults with AML but stable over time.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Cancer stat facts: leukemia - acute myeloid leukemia (AML). National Cancer Institute, 2021 (Accessed 2021)
        • Menzin J.
        • Lang K.
        • Earle C.C.
        • Kerney D.
        • Mallick R.
        The outcomes and costs of acute myeloid leukemia among the elderly.
        Arch Intern Med. Jul 22 2002; 162: 1597-1603https://doi.org/10.1001/archinte.162.14.1597
        • Appelbaum F.R.
        • Gundacker H.
        • Head D.R.
        • et al.
        Age and acute myeloid leukemia.
        Blood. May 1 2006; 107: 3481-3485https://doi.org/10.1182/blood-2005-09-3724
        • van der Holt B.
        • Breems D.A.
        • Berna Beverloo H.
        • et al.
        Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.
        Br J Haematol. Jan 2007; 136: 96-105https://doi.org/10.1111/j.1365-2141.2006.06403.x
        • Grimwade D.
        • Walker H.
        • Harrison G.
        • et al.
        The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
        Blood. Sep 1 2001; 98: 1312-1320https://doi.org/10.1182/blood.v98.5.1312
        • Sorror M.L.
        • Storer B.E.
        • Fathi A.T.
        • et al.
        Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality.
        JAMA Oncol. Dec 1 2017; 3: 1675-1682https://doi.org/10.1001/jamaoncol.2017.2714
        • Sorror M.L.
        • Storb R.F.
        • Sandmaier B.M.
        • et al.
        Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.
        J Clin Oncol. Oct 10 2014; 32: 3249-3256https://doi.org/10.1200/jco.2013.53.8157
        • Loke J.
        • Buka R.
        • Craddock C.
        Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how? Review.
        Front Immunol. 2021; (2021-May-03): 12https://doi.org/10.3389/fimmu.2021.659595
        • Döhner H.
        • Estey E.
        • Grimwade D.
        • et al.
        Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
        Blood. Jan 26 2017; 129: 424-447https://doi.org/10.1182/blood-2016-08-733196
        • Sekeres M.A.
        • Guyatt G.
        • Abel G.
        • et al.
        American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
        Blood Adv. Aug 11 2020; 4: 3528-3549https://doi.org/10.1182/bloodadvances.2020001920
        • Kahl C.
        • Krahl R.
        • Becker C.
        • et al.
        Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).
        J Cancer Res Clin Oncol. Jan 2016; 142: 305-315https://doi.org/10.1007/s00432-015-2045-8
        • Devillier R.
        • Forcade E.
        • Garnier A.
        • et al.
        Allogeneic hematopoietic stem cell transplantation improves outcome of elderly patients with acute myeloid leukemia in first complete remission: a time-dependent and multistate analysis from the French innovative leukemia organization.
        Blood. 2018; 132: 209
        • Sorror M.L.
        • Sandmaier B.M.
        • Storer B.E.
        • et al.
        Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
        Jama. Nov 2 2011; 306: 1874-1883https://doi.org/10.1001/jama.2011.1558
        • Othus M.
        • Kantarjian H.
        • Petersdorf S.
        • et al.
        Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson.
        Leukemia. Feb 2014; 28: 289-292https://doi.org/10.1038/leu.2013.176
        • Wei A.H.
        • Strickland Jr., S.A.
        • Hou J.Z.
        • et al.
        Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study.
        J Clin Oncol. May 20 2019; 37: 1277-1284https://doi.org/10.1200/jco.18.01600
        • DiNardo C.D.
        • Jonas B.A.
        • Pullarkat V.
        • et al.
        Azacitidine and venetoclax in previously untreated acute myeloid leukemia.
        N Engl J Med. 2020; 383: 617-629https://doi.org/10.1056/NEJMoa2012971
        • DiNardo C.D.
        • Stein E.M.
        • de Botton S.
        • et al.
        Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML.
        N Engl J Med. 2018; 378: 2386-2398https://doi.org/10.1056/NEJMoa1716984
        • Pollyea D.A.
        • Winters A.
        • McMahon C.
        • et al.
        Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
        Bone Marrow Transplant. Feb 2022; 57: 160-166https://doi.org/10.1038/s41409-021-01476-7
        • Hilberink J.
        • Hazenberg C.
        • van den Berg E.
        • et al.
        Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: a single center experience of 355 consecutive patients.
        Leuk Res. May 2019; 80: 33-39https://doi.org/10.1016/j.leukres.2019.03.004
        • Phelan R.
        • Arora M.
        • Chen M.
        Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides.
        2020
        • Getta B.M.
        • Kishtagari A.
        • Hilden P.
        • et al.
        Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes.
        Biol Blood Marrow Transplant. Jul 2017; 23: 1078-1086https://doi.org/10.1016/j.bbmt.2017.03.020
        • Jagasia M.H.
        • Greinix H.T.
        • Arora M.
        • et al.
        National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report.
        Biol Blood Marrow Transplant. Mar 2015; 21 (e1): 389-401
        • Herold T.
        • Rothenberg-Thurley M.
        • Grunwald V.V.
        • et al.
        Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
        Leukemia. Dec 2020; 34: 3161-3172https://doi.org/10.1038/s41375-020-0806-0
        • Flannelly C.
        • Tan B.E.
        • Tan J.L.
        • et al.
        Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age.
        Biol Blood Marrow Transplant. Dec 2020; 26: 2335-2345https://doi.org/10.1016/j.bbmt.2020.09.013
        • DuMontier C.
        • Loh K.P.
        • Bain P.A.
        • et al.
        Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review.
        J Clin Oncol. Aug 1 2020; 38: 2558-2569https://doi.org/10.1200/jco.19.02809
        • Olin R.L.
        • Fretham C.
        • Pasquini M.C.
        • et al.
        Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.
        Blood Adv. Jun 23 2020; 4: 2810-2820https://doi.org/10.1182/bloodadvances.2020001719
        • Deschler B.
        • Ihorst G.
        • Schnitzler S.
        • Bertz H.
        • Finke J.
        Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.
        Bone Marrow Transplant. May 2018; 53: 565-575https://doi.org/10.1038/s41409-017-0021-4
        • Sorror M.L.
        • Maris M.B.
        • Storb R.
        • et al.
        Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
        Blood. Oct 15 2005; 106: 2912-2919https://doi.org/10.1182/blood-2005-05-2004
        • Lew M.V.
        • Ren Y.
        • Lowder Y.P.
        • et al.
        Geriatric assessment reveals actionable impairments in hematopoietic stem cell transplantation candidates age 18 to 80 years.
        Transplant Cell Ther. Aug 2022; 28: 498.e1-498.e9https://doi.org/10.1016/j.jtct.2022.05.018
        • Saad M.
        • Loh K.P.
        • Tooze J.A.
        • et al.
        Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia.
        Blood. Dec 3 2020; 136: 2715-2719https://doi.org/10.1182/blood.2020005498
        • Klepin H.D.
        • Geiger A.M.
        • Tooze J.A.
        • et al.
        Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.
        Blood. May 23 2013; 121: 4287-4294https://doi.org/10.1182/blood-2012-12-471680
        • Derman B.A.
        • Kordas K.
        • Ridgeway J.
        • et al.
        Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
        Blood Adv. Nov 26 2019; 3: 3488-3498https://doi.org/10.1182/bloodadvances.2019000790
        • Blood and Marrow Transplant Clinical Trials Network
        BMT CTN protocol 1704 CHARM.
        (Available at) ([Accessed 21 September, 2022])
        • Pidala J.
        • Craig B.M.
        • Lee S.J.
        • Majhail N.
        • Quinn G.
        • Anasetti C.
        Practice variation in physician referral for allogeneic hematopoietic cell transplantation.
        Bone Marrow Transplant. Jan 2013; 48: 63-67https://doi.org/10.1038/bmt.2012.95
        • Kalsi T.
        • Payne S.
        • Brodie H.
        • Mansi J.
        • Wang Y.
        • Harari D.
        Are the UK oncology trainees adequately informed about the needs of older people with cancer?.
        Br J Cancer. May 28 2013; 108: 1936-1941https://doi.org/10.1038/bjc.2013.204
        • Maggiore R.J.
        • Dale W.
        • Hurria A.
        • et al.
        Hematology-oncology fellows’ training in geriatrics and geriatric oncology: findings from an American Society of Clinical oncology-sponsored national survey.
        J Oncol Pract. Nov 2017; 13: e900-e908https://doi.org/10.1200/jop.2017.022111
        • DiNardo C.D.
        • Schuh A.C.
        • Stein E.M.
        • et al.
        Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
        Lancet Oncol. Nov 2021; 22: 1597-1608https://doi.org/10.1016/s1470-2045(21)00494-0
        • DiNardo C.D.
        • Stein E.M.
        • Pigneux A.
        • et al.
        Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
        Leukemia. Nov 2021; 35: 3278-3281https://doi.org/10.1038/s41375-021-01229-x